Manal F. Abdelmalek, Ayako Suzuki, Cynthia Guy, Aynur Unalp‐Arida, Ryan Colvin, Richard J. Johnson, Anna Mae Diehl, for the Nonalcoholic Steatohepatitis Clinical Research Network – 23 May 2010 – The rising incidence of obesity and diabetes coincides with a marked increase in fructose consumption. Fructose consumption is higher in individuals with nonalcoholic fatty liver disease (NAFLD) than in age‐matched and body mass index (BMI)‐matched controls.

Akif Altınbas, Fuat Ekiz, Osman Yuksel – 23 May 2010

Einar Björnsson, Jayant Talwalkar, Sombat Treeprasertsuk, Patrick S. Kamath, Naoki Takahashi, Schuyler Sanderson, Matthias Neuhauser, Keith Lindor – 23 May 2010 – Drug‐induced autoimmune hepatitis (DIAIH) has been reported to be caused by several drugs. There is a lack of data comparing these patients with other patients with autoimmune hepatitis (AIH). A search was performed using the Mayo Clinic diagnostic medical index for AIH patients and DIAIH patients identified over 10 years. Individuals with overlap syndromes and decompensated liver disease were excluded.

Thomas E. Starzl, John J. Fung – 23 May 2010 – Liver transplantation was the product of five interlocking themes. These began in 1958‐1959 with canine studies of then theoretical hepatotrophic molecules in portal venous blood (Theme I) and with the contemporaneous parallel development of liver and multivisceral transplant models (Theme II). Further Theme I investigations showed that insulin was the principal, although not the only, portal hepatotrophic factor.

A. S. Knisely, Diego Vergani – 23 May 2010

Hermann E. Wasmuth, Ralf Weiskirchen – 23 May 2010

Moises Diago, Mitchell L. Shiffman, Jean‐Pierre Bronowicki, Stefan Zeuzem, Maribel Rodriguez‐Torres, Stephen C. Pappas, Andreas Tietz, David R. Nelson – 23 May 2010 – The objective of this analysis was to compare sustained virological response (SVR) and relapse rates in patients with a rapid virological response (RVR, HCV RNA <50 IU/mL at week 4) randomized to 24 or 16 weeks of treatment with peginterferon alfa‐2a (40KD) 180 μg/week plus ribavirin 800 mg/day in the multinational ACCELERATE study.

Florian Grabellus, Knut M. Nowak – 23 May 2010

Melania Manco, Paolo Ciampalini, Valerio Nobili – 23 May 2010

Jun Yu, Bo Shen, Eagle S. H. Chu, Narci Teoh, Kin‐Fai Cheung, Chung‐Wah Wu, Shiyan Wang, Cleo N. Y. Lam, Hai Feng, Junhong Zhao, Alfred S. L. Cheng, Ka‐Fai To, Henry L. Y. Chan, Joseph J. Y. Sung – 23 May 2010 – Although peroxisome proliferator‐activated receptor gamma (PPARγ) agonist have been shown to inhibit hepatocellular carcinoma (HCC) development, the role of PPARγ in hepatocarcinogenesis remains unclear. We investigated the therapeutic efficacy of PPARγ against HCC.